Navigation Links
Gene Linked to 'Dry' Macular Degeneration
Date:8/27/2008

Study also uncovers risks associated with treating 'wet' form of the eye disease

WEDNESDAY, Aug. 27 (HealthDay News) -- Scientists from the United States and China have identified the first gene directly associated with the onset of severe "dry" macular degeneration, one of two forms of age-related macular degeneration that currently threatens the vision of up to nine million older Americans.

The discovery, based on work with both human and mice cells, centers on a specific immune system protein called TLR3. Although helpful in fending off illness when confronted with certain viral infections, this molecule, when routinely activated, was also found to raise the risk for "dry" macular degeneration by attacking infected retinal cells.

But, the study authors also found a genetic silver lining in the form of a mutated version of TLR3 -- a so-called "inactive" or "less active" TLR3 -- that suppresses this retinal death process, seemingly protecting people from the eye disease.

"This represents a major step forward in our understanding of the dry form of macular degeneration," said study co-author Dr. Kang Zhang, a professor of ophthalmology and human genetics at the Shiley Eye Center at the University of California, San Diego, School of Medicine. "And with the identification of this potential target, we can try to develop treatments for a disease which, for the moment, we can't treat."

The findings were expected to be published online Aug. 28 in the New England Journal of Medicine.

But celebration over isolating TLR3's role in dry age-related macular degeneration (AMD) has been tempered by some potentially troubling implications that the new findings seem to have for a cutting-edge investigational treatment recently unveiled to target the so-called "wet" form of AMD.

The treatment in question, known as "RNA interference," or RNAi, works by "silencing" genes that bring about wet AMD. Unfortunately, the treatment appears to simultaneously activate TLR3 -- resulting in a 60 percent spike in retinal cell death among mice and humans genetically susceptible to developing dry AMD. The result: RNAi may help protect against wet AMD while boosting the risk for dry AMD, the study authors said.

"This raises particular concerns regarding RNAi therapy for wet AMD," Zhang said. "But by establishing this link between the treatment for the wet form of AMD and the potential harmful effect on the dry form of the disease, we can perhaps better understand the mechanisms of both diseases."

Age-related macular degeneration is the leading cause of blindness in adults over the age of 60, according to the U.S. National Eye Institute. The progressively worsening disease affects the macula portion of the eye, located in the center of the retina, which enables detailed vision.

The disease can strike in two ways: wet and dry. In its wet form --sometimes referred to as "advanced AMD" -- loss of vision occurs rapidly due to the growth of abnormal blood vessels under the macula, leading to leakage of blood and fluids. In its more slowly progressing dry form, light-sensitive macular cells begin to break down, leading to a blurring of vision in one or both eyes, according to the eye institute.

Addressing the new findings, Rando Allikmets, a professor of ophthalmology, pathology and cell biology at Columbia University, urged restraint.

"I think these results have to be taken with caution, because the association effect of TLR3 with AMD is very small when compared to the disease's association with some other genes," he said. "And there has been already one study saying there is absolutely no association of the TLR3 genetic variant with AMD. So, this raises a question and a need for further edification. It could be that this is just a spurious finding, and there is, in fact, no association with AMD."

More information

For more on age-related macular degeneration, visit the National Eye Institute.



SOURCES: Kang Zhang, M.D., Ph.D., professor of ophthalmology and human genetics, Shiley Eye Center, University of California, San Diego; Rando Allikmets, Ph.D., professor, ophthalmology, pathology and cell biology, Columbia University, New York City; Aug. 28, 2008, New England Journal of Medicine, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
3. Immune deficiency linked to a type of eye cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Clinical depression linked to abnormal emotional brain circuits
6. Air pollution linked to cardiovascular risk indices in healthy young adults
7. High pollution linked to poor lung function growth in children in Mexico City
8. Early Weight Loss in Women Linked to Dementia
9. Vitamin Es lack of heart benefit linked to dosage
10. Sugary Sodas High in Diabetes-Linked Compound
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: